Novo CEO sees obesity pill opening doors to new markets

Novo Nordisk A/S’s obesity pill will allow it to tap into a massive population of patients that have not yet taken GLP-1s , the drugmaker’s chief executive said. The pill version of its blockbuster obesity shot Wegovy will expand the market for these drugs, CEO Mike Doustdar said at an Endpoints event in San Francisco […]

Pfizer CEO Bourla Says Company Looking For ‘Superior’ Results from Weight-Loss Drugs

Pfizer CEO Albert Bourla told Bloomberg’s Katie Greifeld Pfizer is looking for ‘superior results’ while developing and testing further GLP-1 weight loss medications in a crowded market. Bourla also commented on his company’s relationship with the Trump administration as businesses look for stability on pricing and tariffs. He told Bloomberg he is optimistic that uncertainty […]

Semaglutide Attenuates Neuroinflammation in Mice

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown promise in preclinical models of neurodegeneration, with emerging evidence suggesting these effects may be driven by modulation of neuroinflammation. However, the cellular mechanisms underlying GLP-1 RA effects on neuroinflammation remain poorly understood. Here, using a mouse model of lipopolysaccharide-induced neuroinflammation, we investigated how semaglutide coordinates cellular responses […]

Tom Brady joins telehealth startup to help sell GLP-1s

Of all the television personalities on GLP-1s like Ozempic, Tom Brady doesn’t appear to be one of them. You don’t play in the NFL into your mid-40s if you need help losing a few pounds. But the Fox Sports commentator will now be the new “face” of GLP-1s, at least according to a headline by […]